Mechanism of Action:
Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome. Lincomycin is predominantly bacteriostatic in vitro.
Drug Label Information | Brands:
Lincocin®, Pfizer Upjohn
Lincomycin, Swiss Parenterals (Pvt.) Ltd
Lincozed®, Zawadi Healthcare Ltd
Lincomycin is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial associated pseudomembranous colitis, the physician should consider the nature of the infection and the suitability of other alternatives.
Indicated surgical procedures should be performed in conjunction with antibacterial therapy.
The drug may be administered concomitantly with other antimicrobial agents when indicated.
Lincomycin is not indicated in the treatment of minor bacterial infections or viral infections.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Lincomycin and other antibacterial drugs, Lincomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
This drug is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin.
ADVERSE DRUG REACTIONS
Diarrhea, nausea, vomiting, glossitis, stomatitis, abdominal pain, abdominal discomfort , anal pruritus
Skin and subcutaneous tissue disorders
Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis,dermatitis bullous, dermatitis exfoliative, erythema multiforme (see WARNINGS), rash, urticaria, pruritus
Infections and infestations
Vaginal infection, pseudomembranous colitis, Clostridium difficile colitis (see Vaginal infection, pseudomembranous colitis, Clostridium diffi cile colitis
Blood and lymphatic system disorders
Pancytopenia, agranulocytosis, aplastic anemia, leukopenia, neutropenia, thrombocytopenic purpura
Immune system disorders
Anaphylactic reaction , angioedema, serum sickness
Jaundice, liver function test abnormal, transaminases increased
Renal and urinary disorders
Renal impairment, oliguria, proteinuria, azotemia
Hypotension , thrombophlebitis1
Ear and labyrinth disorders
Headache, dizziness, somnolence
General disorders and administration site conditions
Injection site abscess sterile , injection site induration , injection site pain , injection site irritation
- lincomycin increases effects of Neuromascular Junction Blockers by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.
- Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.
- lincomycin, rimabotulinumtoxin B. Either increases effects of the other by pharmacodynamic synergism.Closely monitor for increased neuromuscular blockade.